GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » 3-Year FCF Growth Rate

Genmab AS (OCSE:GMAB) 3-Year FCF Growth Rate : 4.60% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genmab AS 3-Year FCF Growth Rate?

Genmab AS's Free Cash Flow per Share for the three months ended in Sep. 2024 was kr31.06.

During the past 12 months, Genmab AS's average Free Cash Flow per Share Growth Rate was 16.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 4.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 51.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Genmab AS was 189.10% per year. The lowest was -78.70% per year. And the median was 32.75% per year.


Competitive Comparison of Genmab AS's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Genmab AS's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Genmab AS's 3-Year FCF Growth Rate falls into.



Genmab AS 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Genmab AS  (OCSE:GMAB) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Genmab AS 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Genmab AS's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.